Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
大药企是否有望接管大麻股？美国已有3家公司掌控了10份处方药中的8份
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical questions about the future of the cannabis industry, especially if cannabis is federally legalized.
美国联邦贸易委员会（FTC）最近强调药品福利管理员（PBMs）在药品价格上的重要影响，这是由于市场整合。这一趋势对大麻行业的未来提出了重大问题，尤其是在大麻合法化成为联邦法律的情况下。
The Role Of PBMs And Market Influence
PBMs和市场影响的作用
PBMs, such as UnitedHealth Group (NYSE:UNH)'s Optum, CVS Health (NYSE:CVS)'s CVS Caremark and Cigna (NYSE:CI)'s Express Scripts, negotiate discounts, create medication lists covered by insurance and reimburse pharmacies.
PBMs，如UnitedHealth Group（纽交所：UNH）的优健康，CVS Health（纽交所：CVS）的CVS Caremark和Cigna（纽交所：CI）的Express Scripts，协商折扣，创建医保覆盖的药品清单和报销药房。
The FTC's interim report revealed that these three PBMs manage 79% of U.S. prescription drug claims...
FTC的临时报告显示，这三个PBM...
登录免费看全文
登录/注册